HUTCHMED (China) Ltd
fanregratinib
intrahepatic cholangiocarcinoma
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on fanregratinib for intrahepatic cholangiocarcinoma is expected Date TBD.
Primary source
· SEC 6-K
verified 12h ago
“a New Drug Application (NDA) for fanregratinib for the treatment of adult patients with advanced, metastatic or unresectable ICC with fibroblast growth factor receptor (“FGFR”) 2 fusion/rearrangement who have previously received systemic th”